SPP1 is a Wnt/β-catenin target gene (39) and administration of the COX-2 inhibitor parecoxib to APC∆14/+ mice, which display a FAP phenotype, downregulates SPP1 by inhibition of Wnt/β-catenin while decreasing intestinal tumor load and mice morality (40). This evidence concerns the gene FAP and intestinal neoplasm.